rtmark
LearnBonds.com

Will Alphabet Inc (GOOGL) Bet on Bioelectronics Pay Off?

Google’s parent company, Alphabet Inc practically has a hand in every pie in all the fields of human endeavor. One of its divisions, Verily Life Sciences is concerned with using technology to understand and improve human health by merging technology and life sciences. Now, Alphabet’s Verily wants to create minute robots that can cure diseases by deepening research on Bioelectronics as the next phase in solving medical problems.

Alphabet Inc (NASDAQ:GOOG)

Alphabet to use Bioelectronics to cure diseases

Verily and GlaxoSmithKline have reportedly reached an agreement to form a new firm that will develop bioelectronics. Biolectronics is concerned with how electrical signals can be used to fight off diseases in the human body. GlaxoSmithKline and Verily will contributed 540 million pounds ($715 million) over the next seven year to the new firm which will be 55% owned by GSK and 45% owned by Verily.

Moncef Slaoui, GSK’s chairman of global vaccines explains how Bioelectronics work in a statement. He says, “Many of the processes of the human body are controlled by electrical signals firing between the nervous system and the body’s organs, which may become distorted in many chronic diseases… Bioelectronic medicine’s vision is to employ the latest advances in biology and technology to interpret this electrical conversation and to correct the irregular patterns found in disease states, using miniaturised devices attached to individual nerves.”

The new company called Galvani Bioelectronics will have research facilities in the UK and San Francisco.  Kris Famm, GSK’s head of bioelectronics research and president of the new firm revealed that they plan to have the first bioelectronics ready for regulatory approval in the next years. In his words, “We have had really promising results in animal tests, where we’ve shown we can address some chronic diseases with this mechanism, and now we are bringing that work into the clinic.”

Will Alphabet’s bets pay off?

Alphabet underwent a restructuring last year to separate its core Google business from other moonlighting projects or “bets” as they are called. The bets are innovative/new projects from which the firm hopes to unlock its next billion-dollar opportunity.

One of Alphabet’s bet is working on self-driving cars, another bet is building drones, and another bet wants to extend human life. Verily is one of the few bets at that has the brightest prospects at Alphabet. Verily is developing a “Smart Contact Lens” with an embedded glucose sensor that people with diabetes can use to measure glucose level in their tears continuously.

It is still a little too early to make a verdict on whether the firm’s bets will pay off or not. However, it is obvious that the restructuring that led to the creation of the bets has improved Alphabet’s stock in the investment community. The shares of Alphabet currently trade at $800.12 per share and the stock has gained 21.79% since its restructuring last year. The stock has tracked the general stock market this year and it sports 2.84% year-to-date gains.

Trusted & Regulated Stock & CFD Brokers

Rating

What we like

  • 0% Fees on Stocks
  • 5000+ Stocks, ETFs and other Markets
  • Accepts Paypal Deposits

Min Deposit

$200

Charge per Trade

Zero Commission

Rating

64 traders signed up today

Visit Now

75% of investors lose money when trading CFDs.

Available Assets

  • Total Number of Stocks & Shares5000+
  • US Stocks
  • German Stocks
  • UK Stocks
  • European
  • ETF Stocks
  • IPO
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 Zero Commission
  • NASDAQ Zero Commission
  • DAX Zero Commission
  • Facebook Zero Commission
  • Alphabet Zero Commission
  • Tesla Zero Commission
  • Apple Zero Commission
  • Microsoft Zero Commission

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
  • Paypall
  • Skrill
  • Neteller

Rating

What we like

  • Sign up today and get $5 free
  • Fractals Available
  • Paypal Available

Min Deposit

$0

Charge per Trade

$1 to $9 PCM

Rating

Visit Now

Investing in financial markets carries risk, you have the potential to lose your total investment.

Available Assets

  • Total Number of Shares999
  • US Stocks
  • German Stocks
  • UK Stocks
  • European Stocks
  • EFTs
  • IPOs
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 $1 - $9 per month
  • NASDAQ $1 - $9 per month
  • DAX $1 - $9 per month
  • Facebook $1 - $9 per month
  • Alphabet $1 - $9 per month
  • Telsa $1 - $9 per month
  • Apple $1 - $9 per month
  • Microsoft $1 - $9 per month

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
All trading carries risk. Views expressed are those of the writers only. Past performance is no guarantee of future results. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.
Avatar

Victor Alagbe is a seasoned business and finance writer with a specialty in writing about how to invest for the long-term in healthcare, pharmacology, energy and tech stocks. His long-term focus is on stocks that provide a nice mix of growth and income. For the short term, he passionately writes about trading stock options for the excitement and leverage that stock options offer.